All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
VivoCAR™ Anti-ALPPL2 (h1E8) h(CD28-41BB-CD3z) CAR saRNA utilizes a high-efficiency saRNA backbone to drive the humanized 1E8 clone. In vivo, h1E8 is critical for targeting ALPPL2 on mesothelioma and testicular cancers. The saRNA platform achieves a biological magnification effect, ensuring robust CAR expression from a low dose. This enables T cells to reprogram in situ and target the tumor-specific ALPPL2 antigen while maintaining a dose-sparing approach for improved safety in systemic administration.
There are currently no customer reviews or questions for VivoCAR™ Anti-ALPPL2 (h1E8) h(CD28-41BB-CD3z) CAR saRNA (XS-0326-XU85). Click the button below to contact us or submit your feedback about this product.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
NEWSLETTER
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTER
NEW SOLUTION
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTION
NOVEL TECHNOLOGY
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGY
NEW SOLUTION
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION